<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinform Adv</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinform Adv</journal-id>
    <journal-id journal-id-type="publisher-id">bioadv</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics Advances</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2635-0041</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9154024</article-id>
    <article-id pub-id-type="pmid">35669345</article-id>
    <article-id pub-id-type="doi">10.1093/bioadv/vbac032</article-id>
    <article-id pub-id-type="publisher-id">vbac032</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Paper</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Cancer</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>NeoSplice: a bioinformatics method for prediction of splice variant neoantigens</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Chai</surname>
          <given-names>Shengjie</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff2" ref-type="aff">2</xref>
        <xref rid="vbac032-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6517-0439</contrib-id>
        <name>
          <surname>Smith</surname>
          <given-names>Christof C</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff3" ref-type="aff">3</xref>
        <xref rid="vbac032-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kochar</surname>
          <given-names>Tavleen K</given-names>
        </name>
        <xref rid="vbac032-aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hunsucker</surname>
          <given-names>Sally A</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Beck</surname>
          <given-names>Wolfgang</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Olsen</surname>
          <given-names>Kelly S</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vensko</surname>
          <given-names>Steven</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Glish</surname>
          <given-names>Gary L</given-names>
        </name>
        <xref rid="vbac032-aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Armistead</surname>
          <given-names>Paul M</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff5" ref-type="aff">5</xref>
        <xref rid="vbac032-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0853-6099</contrib-id>
        <name>
          <surname>Prins</surname>
          <given-names>Jan F</given-names>
        </name>
        <xref rid="vbac032-aff2" ref-type="aff">2</xref>
        <xref rid="vbac032-aff6" ref-type="aff">6</xref>
        <xref rid="vbac032-FM1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1762-2282</contrib-id>
        <name>
          <surname>Vincent</surname>
          <given-names>Benjamin G</given-names>
        </name>
        <xref rid="vbac032-aff1" ref-type="aff">1</xref>
        <xref rid="vbac032-aff2" ref-type="aff">2</xref>
        <xref rid="vbac032-aff3" ref-type="aff">3</xref>
        <xref rid="vbac032-aff5" ref-type="aff">5</xref>
        <xref rid="vbac032-aff7" ref-type="aff">7</xref>
        <xref rid="vbac032-cor1" ref-type="corresp"/>
        <!--benjamin_vincent@med.unc.edu-->
        <xref rid="vbac032-FM1" ref-type="author-notes"/>
      </contrib>
    </contrib-group>
    <aff id="vbac032-aff1"><label>1</label><institution>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</institution>, Chapel Hill, NC, 27514, <country country="US">USA</country></aff>
    <aff id="vbac032-aff2"><label>2</label><institution>Curriculum in Bioinformatics and Computational Biology, UNC School of Medicine</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <aff id="vbac032-aff3"><label>3</label><institution>Department of Microbiology and Immunology, UNC School of Medicine</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <aff id="vbac032-aff4"><label>4</label><institution>Department of Chemistry, University of North Carolina</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <aff id="vbac032-aff5"><label>5</label><institution>Division of Hematology, Department of Medicine, UNC School of Medicine</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <aff id="vbac032-aff6"><label>6</label><institution>Department of Computer Science, University of North Carolina</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <aff id="vbac032-aff7"><label>7</label><institution>Computational Medicine Program, UNC School of Medicine</institution>, Chapel Hill, NC, 27599, <country country="US">USA</country></aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Lengauer</surname>
          <given-names>Thomas</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <fn id="vbac032-FM1">
        <p>Shengjie Chai and Christof C Smith wish it to be known that these authors contributed equally.</p>
      </fn>
      <corresp id="vbac032-cor1">To whom correspondence should be addressed. <email>benjamin_vincent@med.unc.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-05-06">
      <day>06</day>
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <volume>2</volume>
    <issue>1</issue>
    <elocation-id>vbac032</elocation-id>
    <history>
      <date date-type="received">
        <day>02</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>14</day>
        <month>4</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>03</day>
        <month>5</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>04</day>
        <month>5</month>
        <year>2022</year>
      </date>
      <date date-type="corrected-typeset">
        <day>26</day>
        <month>5</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="vbac032.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Splice variant neoantigens are a potential source of tumor-specific antigen (TSA) that are shared between patients in a variety of cancers, including acute myeloid leukemia. Current tools for genomic prediction of splice variant neoantigens demonstrate promise. However, many tools have not been well validated with simulated and/or wet lab approaches, with no studies published that have presented a targeted immunopeptidome mass spectrometry approach designed specifically for identification of predicted splice variant neoantigens.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>In this study, we describe NeoSplice, a novel computational method for splice variant neoantigen prediction based on (i) prediction of tumor-specific k-mers from RNA-seq data, (ii) alignment of differentially expressed k-mers to the splice graph and (iii) inference of the variant transcript with MHC binding prediction. NeoSplice demonstrates high sensitivity and precision (&gt;80% on average across all splice variant classes) through <italic toggle="yes">in silico</italic> simulated RNA-seq data. Through mass spectrometry analysis of the immunopeptidome of the K562.A2 cell line compared against a synthetic peptide reference of predicted splice variant neoantigens, we validated 4 of 37 predicted antigens corresponding to 3 of 17 unique splice junctions. Lastly, we provide a comparison of NeoSplice against other splice variant prediction tools described in the literature. NeoSplice provides a well-validated platform for prediction of TSA vaccine targets for future cancer antigen vaccine studies to evaluate the clinical efficacy of splice variant neoantigens.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>
          <ext-link xlink:href="https://github.com/Benjamin-Vincent-Lab/NeoSplice" ext-link-type="uri">https://github.com/Benjamin-Vincent-Lab/NeoSplice</ext-link>
        </p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics Advances</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health Clinical Center</institution>
            <institution-id institution-id-type="DOI">10.13039/100000098</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>1F30CA225136</award-id>
        <award-id>5R01CA201225</award-id>
        <award-id>R37CA247676</award-id>
        <award-id>T32CA196589</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>University of North Carolina University Cancer Research Fund</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Recent advances in immunotherapy drugs, such as CTLA-4 and PD-1 blocking antibodies (immune checkpoint inhibitors), have highlighted the capacity of induced anti-tumor immune responses to yield improved survival for cancer patients (<xref rid="vbac032-B9" ref-type="bibr">Hellmann <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B10" ref-type="bibr">Hodi <italic toggle="yes">et al.</italic>, 2010</xref>; <xref rid="vbac032-B21" ref-type="bibr">Larkin <italic toggle="yes">et al.</italic>, 2019</xref>). In parallel with the development of immune checkpoint inhibitors which broadly reverse effector T-cell suppression, there has also been development of therapeutic vaccines that selectively stimulate anti-tumor T cells to expand and kill tumor cells (<xref rid="vbac032-B12" ref-type="bibr">Ito <italic toggle="yes">et al.</italic>, 2015</xref>; <xref rid="vbac032-B19" ref-type="bibr">Keskin <italic toggle="yes">et al.</italic>, 2019; Ott <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B30" ref-type="bibr">Sahin <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B31" ref-type="bibr">Schreiber <italic toggle="yes">et al.</italic>, 2011</xref>; <xref rid="vbac032-B32" ref-type="bibr">Schumacher and Schreiber, 2015</xref>). Tumor-specific peptide epitopes that are generated from mutated genes and presented on cell surface MHC molecules, known as neoantigens, are attractive targets for therapeutic vaccination given the lack of central tolerance and corresponding presence of endogenous T cells that recognize them (<xref rid="vbac032-B32" ref-type="bibr">Schumacher and Schreiber, 2015</xref>). Recent studies have shown that neoantigen targeted therapy can yield improved anti-tumor immune responses in patients with advanced and metastatic tumors (<xref rid="vbac032-B26" ref-type="bibr">Ott <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B30" ref-type="bibr">Sahin <italic toggle="yes">et al.</italic>, 2017</xref>).</p>
    <p>The vast majority of neoantigens in tumors are patient-specific rather than shared between patients. It is therefore essential for neoantigens to be predicted for each patient in a genome-wide fashion for use in therapeutic vaccination (<xref rid="vbac032-B32" ref-type="bibr">Schumacher and Schreiber, 2015</xref>). Currently, most available neoantigen prediction methods focus on predicting neoantigens derived from single-nucleotide variant (SNV)-derived missense mutations or insertion/deletion (indel) mutations (<xref rid="vbac032-B35" ref-type="bibr">Smith <italic toggle="yes">et al.</italic>, 2019</xref>). Typical neoantigen prediction pipelines involve whole-exome sequencing variant calling between tumor and matched-normal samples, RNA sequencing (RNA-seq) quantification of highly expressed tumor-specific mutations and prioritizing mutation derived neo-epitopes using (among other methods) predicted binding affinities to MHC molecules expressed by the patient (<xref rid="vbac032-B11" ref-type="bibr">Hundal <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="vbac032-B17" ref-type="bibr">Kardos <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="vbac032-B20" ref-type="bibr">Kim <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B26" ref-type="bibr">Ott <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B28" ref-type="bibr">Rajasagi <italic toggle="yes">et al.</italic>, 2014; Sahin <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B36" ref-type="bibr">Smith <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="vbac032-B35" ref-type="bibr">2019</xref>; <xref rid="vbac032-B39" ref-type="bibr">Turajlic <italic toggle="yes">et al.</italic>, 2017</xref>; <xref rid="vbac032-B40" ref-type="bibr">Yarchoan <italic toggle="yes">et al.</italic>, 2017</xref>).</p>
    <p>While techniques to identify and apply neoantigens for therapeutic vaccines have shown promise in several cancer types, their application may be limited in cancers that contain few somatic mutations. This has led to the investigation of alternative tumor-specific antigens (TSAs) for application in targeted therapies, including antigens derived from gene fusions, mutational frameshifts, endogenous retroviral and viral genes and splice variant sources (<xref rid="vbac032-B35" ref-type="bibr">Smith <italic toggle="yes">et al.</italic>, 2019</xref>). An example of a low mutation tumor is acute myeloid leukemia (AML), where somatic mutation rates are notably lower in comparison to other cancer types (<xref rid="vbac032-B2" ref-type="bibr">Cancer Genome Atlas Research Network, 2013</xref>). However, mutations in spliceosomal genes and genome-wide aberrant splicing events are common in patients with AML (<xref rid="vbac032-B4" ref-type="bibr">de Necochea-Campion, 2016</xref>; <xref rid="vbac032-B22" ref-type="bibr">Lee <italic toggle="yes">et al.</italic>, 2016</xref>). To extend therapeutic neoantigen targeting to AML and other low mutation tumors with significant alternative splicing, it will be critical to identify splice variant neoantigens. Yet, the prediction of neoantigens from tumor-specific splice variations presents significant computational challenges. Recently, two splice variant neoantigen prediction methods were reported with analysis of the Cancer Genome Atlas (TCGA) pan-cancer dataset (<xref rid="vbac032-B13" ref-type="bibr">Jayasinghe <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B16" ref-type="bibr">Kahles <italic toggle="yes">et al.</italic>, 2018</xref>). However, these tools were not designed to predict the full length splice variant transcript, simply the alternative splice junctions themselves. As such, predicted variant junctions are limited in their capacity to predict transcriptional start sites and translational reading frames. Other tools for prediction of splice variant junctions (<xref rid="vbac032-B1" ref-type="bibr">Brooks <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbac032-B15" ref-type="bibr">Kahles <italic toggle="yes">et al.</italic>, 2016</xref>; <xref rid="vbac032-B29" ref-type="bibr">Rogers <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="vbac032-B33" ref-type="bibr">Shen <italic toggle="yes">et al.</italic>, 2014</xref>; <xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2020</xref>), splice variant neoantigens (<xref rid="vbac032-B34" ref-type="bibr">Smart <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2020</xref>) and somatic mutations that predict for alternative splicing (<xref rid="vbac032-B13" ref-type="bibr">Jayasinghe <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B24" ref-type="bibr">Mort <italic toggle="yes">et al.</italic>, 2014</xref>) have also been reported in the literature. However, many tools lack robust evaluation of performance characteristics using <italic toggle="yes">in silico</italic> simulated data (<xref rid="vbac032-B34" ref-type="bibr">Smart <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2020</xref>). More importantly, few tools provide proteomic validation of predicted splice variant neoantigens (<xref rid="vbac032-B34" ref-type="bibr">Smart <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2020</xref>), with no tool providing immunopeptidome validation against a synthetic peptide reference of predicted antigens. As such, the true biological performance of these tools cannot be evaluated. Altogether, the paucity of robust splice variant neoantigen prediction tools has limited the capacity to study the therapeutic potential of these semi-public TSAs, with no study to date demonstrating concrete evidence in favor of anti-tumor immunity generated by splice variant neoantigens. The need for robust TSA prediction tools is underscored by recent studies providing growing evidence supporting the importance of splice variant neoantigens and other alternative TSA in antitumor immunity (<xref rid="vbac032-B6" ref-type="bibr">Ehx <italic toggle="yes">et al.</italic>, 2021</xref>).</p>
    <p>We developed NeoSplice to address the challenge of accurate computational prediction of splice variant neoantigens. Using a Burrows Wheeler Transform (BWT) based algorithm to identify tumor-specific k-mers and a splice graph to determine whether such a k-mer represents a tumor-specific splice junction in a coding region and its corresponding amino-acid sequence, NeoSplice allows for specific and comprehensive prediction of splice variant neoantigens using tumor and matched-normal RNA-seq data, without requiring matched DNA sequencing data. In this report, we describe the NeoSplice method, validating performance characteristics using <italic toggle="yes">in silico</italic> simulated RNA-seq data. We then apply NeoSplice to TCGA LAML dataset, demonstrating significantly greater sharing of splice variant-derived neoantigens as compared to SNV-derived neoantigens. Lastly, we biologically validate NeoSplice’s predictions in the K562.A2 AML cell line, using mass spectrometry targeted identification of predicted splice variant neoantigens from the immunopeptidome.</p>
  </sec>
  <sec>
    <title>2 Methods</title>
    <sec>
      <title>2.1 The NeoSplice method</title>
      <p>Multiple steps are needed to identify a novel splice that occurs specifically in tumor cell transcripts whose translation will result in a neopeptide that can be targeted by T cells (<xref rid="vbac032-F1" ref-type="fig">Fig. 1</xref>):</p>
      <fig position="float" id="vbac032-F1">
        <label>Fig. 1.</label>
        <caption>
          <p>Overview of the NeoSplice method. BAM files from tumor and matched-normal samples generated from a splice-aware aligner are input into the NeoSplice algorithm. Step 1: The multi-string BWT tool based on a variant of the Burrows Wheeler transform (BWT) builds the multi-string BWT data structure for tumor and normal RNA-seq bam files. Step 2: The splice graphs are constructed from the tumor RNA-seq bam files. A depth-first search process operating in lockstep on the tumor and normal BWT data structures identifies all tumor-specific k-mers. The tumor-specific k-mers are mapped onto the splice graphs using CIGAR strings. Step 3: Graph traversal infers the tumor-specific splice junction containing partial transcript isoforms within an open reading frame by taking advantage of using paired-end read information and annotated transcript information. Sequences spanning tumor-specific splice junctions are translated into amino acid space, filtering against a reference peptidome. Remaining peptide sequences are run through MHC binding prediction software, with predicted binders representing putative splice variant neoantigens</p>
        </caption>
        <graphic xlink:href="vbac032f1" position="float"/>
      </fig>
      <list list-type="bullet">
        <list-item>
          <p>Step 1: Tumor-specific k-mer generation. Using one RNA-seq dataset <bold><italic toggle="yes">T</italic></bold> of tumor cells and one RNA-seq dataset <bold><italic toggle="yes">N</italic></bold> of normal cells, tumor-specific k-mer sequences present abundantly in the transcriptome of the tumor cell, but not/rarely expressed in the normal cells are identified.</p>
        </list-item>
        <list-item>
          <p>Step 2: Prediction of splice variant transcripts. The splice graph <bold><italic toggle="yes">G</italic></bold> from the tumor cell RNA-seq data is built, and tumor-specific k-mers from above are mapped to novel splice variant transcripts. Gencode annotations are used to determine whether the novel splice lies within a protein coding region and infer the reading frame of the transcript.</p>
        </list-item>
        <list-item>
          <p>Step 3: Prediction of splice variant neoantigens. Novel splice junctions contained within each splice variant transcript are translated in the inferred open reading frame. MHC binding affinity prediction is performed on translated peptide sequences to determine which novel regions may yield a neopeptide.</p>
        </list-item>
      </list>
      <p>Further breakdown and details of each step is described in <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref>.</p>
    </sec>
    <sec>
      <title>2.2 Generation of simulated reads and performance characterization</title>
      <p>Protein coding regions of annotated hg38 transcripts were modified to generate tumor-specific splice junctions resulting in novel transcripts. One tumor-specific splice junction type was selected from exon skipping splice junction type, partial exon loss splice junction type or partial intron gain splice junction type for data simulation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>). These events cover the majority of splicing abnormalities observed in AML. For each chromosome, five protein coding genes with greater than or equal to eight annotated transcript isoforms were randomly selected. One tumor-specific splice junction per selected gene was then simulated by randomly choosing a combination of donor splice site and acceptor splice site that does not match any splice junctions in the annotated protein coding regions of transcripts for that gene and forms a potential novel splice junction with specified splice junction type compared with reference transcripts. The selected novel splice junction was then applied to all annotated transcripts of that gene. Reference transcripts for comparison to tumor transcripts were written to a separate GTF file and used as normal data. Transcripts that cannot form the specified splice junction type by applying the novel splice junction and genes with no possible tumor-specific splice junctions were excluded from simulated tumor and normal data.</p>
      <p>RNA-seq simulator Polyester (v1.9.754) (<xref rid="vbac032-B7" ref-type="bibr">Frazee <italic toggle="yes">et al.</italic>, 2015</xref>) was used to simulate reads using the generated GTF file as input. One thousand 100 bp paired-end reads were simulated for each transcript in the GTF file. 20 random bootstrap tumor-normal pair datasets were simulated in order to obtain more general results. STAR 2.7.5e (<xref rid="vbac032-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic>, 2013</xref>) was run using simulated reads as input to generate bam file and splice junction output SJ.out.tab. Splice junctions identified by STAR in tumor and normal with less than or equal to 10 uniquely mapping reads spanning the splice junction were filtered. Then the splice junctions in tumor that do not present in splice junctions in normal were considered as ground truth tumor-specific splice junctions. The STAR output bam file was then run through NeoSplice (T_min = 21, N_max = 3), comparing predicted versus simulated splice variants for performance calculations. ASNEO (<xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic>, 2020</xref>) was run with default parameters using STAR splice junction output SJ.out.tab as input file.</p>
    </sec>
    <sec>
      <title>2.3 Generation, culture and mRNA sequencing of K562.A2 cell line</title>
      <p>The K562 (ATCC<sup>®</sup> CCL-243™) (<xref rid="vbac032-B23" ref-type="bibr">Lozzio and Lozzio, 1975</xref>) cell line transduced with a retroviral vector to stably express HLA-A*02:01 (K562.A2) was a kind gift from Dr. Barbara Savoldo (The University of North Carolina at Chapel Hill). The cells were cultured in RPMI 1640 (Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc., GE Healthcare), 100 U/ml penicillin-streptomycin (Gibco, Thermo Fisher Scientific) and 2 mM <sc>l</sc>-glutamine (Gibco, Thermo Fisher Scientific). RNA was isolated from K562.A2 cells using Qiagen’s RNeasy Plus Mini Kit, with RNA eluted in RNase-free water. The sequencing library was prepared at the High Throughput Sequencing Facility (The University of North Carolina at Chapel Hill), using the KAPA Stranded mRNA-Seq Kit Illumina Platforms (Roche Sequencing), and paired-end sequencing (150 cycles/end) was performed on an Illumina HiSeq4000.</p>
    </sec>
    <sec>
      <title>2.4 Isolation and mRNA sequencing of CD34+ cells</title>
      <p>Four leukapheresis products from GCSF mobilized healthy allogeneic stem cell donors that were to be discarded otherwise were thawed, and PBMCs were isolated using Ficoll-Paque gradient centrifugation. Lineage positive cells were removed using the Lineage Depletion Kit (Miltenyi), and CD34+ cells were isolated from the lineage-depleted PBMCs using the CD34 Microbead Kit, Ultrapure (Miltenyi). Total RNA was purified using the RNeasy Plus Mini Kit (Qiagen). The sequencing libraries were prepared at the High Throughput Sequencing Facility (The University of North Carolina at Chapel Hill) using the TruSeq RNA Sample Prep Kit (Illumina), and pair-end sequencing (100 cycles/end) was performed on an Illumina HiSeq2000.</p>
    </sec>
    <sec>
      <title>2.5 Splice variant neoantigen prediction for K562.A2 and TCGA LAML</title>
      <p>For the K562.A2 cell line, STAR 2.7.5e (<xref rid="vbac032-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic>, 2013</xref>) and ABRA2 2.19 (<xref rid="vbac032-B25" ref-type="bibr">Mose <italic toggle="yes">et al.</italic>, 2019</xref>) were used for RNA-seq read alignment to the GENCODE GRCh38.p13 human reference. STAR two-pass mode aligned RNA-seq bam files for TCGA tumor and adjacent normal pairs were downloaded from GDC (<ext-link xlink:href="https://portal.gdc.cancer.gov" ext-link-type="uri">https://portal.gdc.cancer.gov</ext-link>) (<italic toggle="yes">n</italic> = 137). CD34+ hematopoietic stem cell RNA-seq data were used as reference normal data. NeoSplice was run on the K562.A2 cell line RNA-seq BAM file to predict splice variant neoantigens. In the tumor-specific k-mer searching stage, tumor thresholds of T_min = 21 and N_max = 3 were used. Tumor-specific k-mers length were restricted to be at most 90% of read length. In the splice graph generation stage, the minimum number of supporting reads for including SNVs, insertions and deletions in the splice graph were set to 10 and the <italic toggle="yes">P</italic>-value threshold for calling SNV edges was set to 0.000005. Tumor-specific k-mer graph paths that contain splice junctions found by RNA-seq alignment to be supported by at least 20 reads in tumor RNA-seq data but supported by &lt;3 reads in normal RNA-seq data were considered. Tumor-specific k-mer graph paths supported by &lt;15 tumor-specific k-mer-including reads were filtered. Peptides that were also present in GRCh38.p13 reference peptidome generated by translating reference protein coding transcripts in the Gencode GFF3 file (gencode.v35.annotation.gff3) were filtered. Mutant peptides were run through netMHCpan4.0 (<xref rid="vbac032-B14" ref-type="bibr">Jurtz <italic toggle="yes">et al.</italic>, 2017</xref>) (peptide length 8-11mer) for HLA binding prediction, using HLA-A*02:01 for K562.A2 and OptiType (<xref rid="vbac032-B37" ref-type="bibr">Szolek <italic toggle="yes">et al.</italic>, 2014</xref>) calls available from GDC. Predicted neoantigens were defined as peptides with predicted binding affinity &lt;500 nM (<xref rid="vbac032-B28" ref-type="bibr">Rajasagi <italic toggle="yes">et al.</italic>, 2014</xref>).</p>
    </sec>
    <sec>
      <title>2.6 SNV neoantigen prediction for TCGA LAML</title>
      <p>SNV-derived neoantigens for TCGA LAML samples were derived using GDC MAF files, using methods adopted from <xref rid="vbac032-B38" ref-type="bibr">Thorsson <italic toggle="yes">et al.</italic> (2019)</xref>. Somatic nonsynonymous coding SNVs were extracted from the MC3 variant file (mc3.v0.2.8.PUBLIC.maf) with the following filters: FILTER in ‘PASS’, ‘wga’, ‘native_wga_mix’; NCALLERS &gt; 1; Variant_Classification = ‘Missense_Mutation’; and Variant_Type = ‘SNP’. For each SNV, the Ensembl protein reference sequence was obtained, and the minimal peptide encompassing the mutation site plus 10 amino acids up and downstream of the mutation site was extracted (21 aa long peptide). If the mutation occurred within 10 amino acids of the N- or C-terminal end of the protein, all available sequence between the mutation and start/end of the protein was taken, resulting in a minimal peptide shorter than 21aa. The variant position within the minimal peptide was recorded, and the mutation was applied to the minimal peptide, resulting in a mutant minimal peptide. Mutant peptides were run through netMHCpan4.0 (<xref rid="vbac032-B14" ref-type="bibr">Jurtz <italic toggle="yes">et al.</italic>, 2017</xref>) (peptide length 8-11mer) for HLA binding prediction, using OptiType (<xref rid="vbac032-B37" ref-type="bibr">Szolek <italic toggle="yes">et al.</italic>, 2014</xref>) HLA calls available from GDC. Predicted neoantigens were defined as peptides with predicted binding affinity &lt;500 nM.</p>
    </sec>
    <sec>
      <title>2.7 HLA peptide isolation</title>
      <p>Peptide epitopes presented by HLA-A*02:01 were isolated using a modified version of the protocol from <xref rid="vbac032-B27" ref-type="bibr">Park <italic toggle="yes">et al.</italic> (2017)</xref>. Five hundred million K562.A2 cells were washed 3 times in Dulbecco’s phosphate buffered saline (DPBS; Gibco, Thermo Fisher Scientific) and lysed in 50 ml of ice-cold IP-lysis buffer: 1x DPBS, 1% Triton X-100 (Sigma-Aldrich), 5 mM EDTA (Thermo Fisher Scientific), 1× Halt Protease Inhibitor (Thermo Fisher Scientific), 1 mg/ml leupeptin (R&amp;D Systems) and 1 mM PMSF (phenylmethylsulfonyl fluoride; Sigma-Aldrich). The lysate was incubated on ice for an hour and vortexed every 15 min, then cleared by centrifugation for 30 min at 3000×<italic toggle="yes">g</italic> at 4°C. The protein concentration of the supernatant was measured using the Coomassie Plus Bradford Protein Assay (Thermo Fisher Scientific). The cleared lysate was incubated on a rotator overnight at 4°C with 2 g of HLA-A*02-specific BB7.2 Ab (BioLegend) per mg of lysate protein, followed by a 4 hour incubation with Protein A/G Ultralink Resin (Thermo Fisher Scientific). After washing 3 times with DPBS, the resin was transferred to a 2 mL centrifuge column (Pierce, Thermo Fisher Scientific). HLA-A*02:01-peptide complexes were eluted by gravity flow using ice-cold 0.1 N acetic acid (Thermo Fisher Scientific) in 5 fractions, each equal to a column volume. The fraction containing eluted proteins was determined using the Bradford Assay, and glacial acetic acid was added to 10% of the final volume of this fraction to separate the peptides from HLA-A*02:01. The sample was filtered through a 10 kDa regenerated cellulose filter (Amicon, EMD Millipore) to separate the peptides from larger proteins and stored at −80°C until analysis.</p>
    </sec>
    <sec>
      <title>2.8 Mass spectrometry analysis of the immunopeptidome</title>
      <p>Electrospray ionization coupled to differential ion mobility spectrometry-mass spectrometry (ESI-DIMS-MS) was used at a dispersion field (ED) of 24 kV/cm and a compensation voltage of 2.0 V. The mass spectrometer was tuned to optimize transmision of singly charged species that range from m/z 864 to m/z 1348. The MS/MS spectra acquired from collision-induced dissociation (CID) of the singly charged species from the cell sample were compared and matched with the MS/MS spectra obtained from synthetic peptide standards (Flashpure Custom Peptide Array, New England Peptide, Inc.), predicted from NeoSplice analysis of the K562.A2 cell line. A library of the predicted peptide standards was developed using the instrument vendor software (Bruker DataAnalysis LibraryEditor). The software was used to compare MS/MS spectra from real samples to a spectral library of predicted peptide standards obtained using the same instrumental conditions. The Fit score (F) indicates how well masses and intensities of the library spectrum (assumed to be pure) and acquired spectrum (contains other signals) agree, with a maximum score of 1000. An acquired MS/MS spectrum identified with an F score of &gt;700 was selected as a positive match.</p>
    </sec>
    <sec>
      <title>2.9 Availability</title>
      <p>The NeoSplice software is available on the GitLab page: <ext-link xlink:href="https://github.com/Benjamin-Vincent-Lab/NeoSplice" ext-link-type="uri">https://github.com/Benjamin-Vincent-Lab/NeoSplice</ext-link>. The Docker image for NeoSplice is available on: <ext-link xlink:href="https://hub.docker.com/r/benjaminvincentlab/neosplice" ext-link-type="uri">https://hub.docker.com/r/benjaminvincentlab/neosplice</ext-link>.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <sec>
      <title>3.1 Performance and resource utilization characteristics</title>
      <p>The main computational challenge for prediction of splice variant neoantigens is inference of tumor-specific splice junctions contained within transcripts. To assess the performance of NeoSplice, we simulated 20 RNA-seq datasets using hg38 splice junction annotations to include novel, unannotated protein coding splice junctions for each splice junction type, including exon skipping splice junctions (∼40% of all alternative splicing events in higher eukaryotes), partial intron gain splice junctions (&lt;5% of all alternative splicing events in vertebrate and invertebrates), and partial exon loss splice junctions (∼25% of all alternative splice events in higher eukaryotes) (<xref rid="vbac032-B18" ref-type="bibr">Keren <italic toggle="yes">et al.</italic>, 2010</xref>). Five protein coding genes were selected for each chromosome. One tumor-specific splice junction was selected for each gene if a tumor-specific splice junction was supported; genes with no possible tumor-specific splice junctions were excluded. We then used Polyester31 to simulate 100 bp paired-end reads from the simulated transcript GTF files, with 8000 reads simulated per transcript. The median sensitivity and precision values of NeoSplice were greater than 0.8 for all types of splice junctions except intron gain sensitivity (0.71) (<xref rid="vbac032-F2" ref-type="fig">Fig. 2A</xref>). The performance of NeoSplice was also compared with another splice variant neoantigen prediction tool, ASNEO23, showing significantly improved median sensitivity and precision values (<xref rid="vbac032-F2" ref-type="fig">Fig. 2A</xref>). ASNEO relies upon an external reference for normal samples (hg19 reference (<xref rid="vbac032-B3" ref-type="bibr">Church <italic toggle="yes">et al.</italic>, 2011</xref>) and GTEx (<xref rid="vbac032-B8" ref-type="bibr">GTEx Consortium, 2017</xref>)), highlighting the benefits and importance for using matched normal data for accurate prediction of splice variants. Notably, ASNEO relies upon a built-in reference derived from hg19 while NeoSplice’s reference can be user-selected. As we were unable to change ASNEO’s reference, performance variation between the two tools may be attributable to both functional differences between the two algorithms as well as NeoSplice’s use of hg38.</p>
      <fig position="float" id="vbac032-F2">
        <label>Fig. 2.</label>
        <caption>
          <p>Performance and resource usage of NeoSplice on simulated data. (<bold>A</bold>) Sensitivity and precision for simulated splice variant transcripts, including those derived from exon skipping, exon loss, or intron gain. Values represent the mean performance across 22 chromosomes (up to 5 splice variant junctions per chromosome) for each of 20 total simulated samples. (<bold>B</bold>) Average runtime (left) and max resident set size (RSS; right), with error bars representing the maximum and minimum times across three simulated samples. Runtime is defined as the elapsed time and RSS is the amount of memory requested by NeoSplice from the operating system as reported by the ‘sacct’ command, as measured on an Intel Xeon ES-E5620 2.4 GHz CPU or ES-E5520 2.27 GHz CPU</p>
        </caption>
        <graphic xlink:href="vbac032f2" position="float"/>
      </fig>
      <p>To determine resource requirements of NeoSplice, we measured the running time and memory consumption using simulated transcript sets containing 1000, 4000 and 8000 reads per transcript. Runtime and memory consumption (maximum resident-shared size; recorded using ‘sacct’ command) increase linearly in proportion to the number of reads simulated per transcript, as expected for NeoSplice (<xref rid="vbac032-F2" ref-type="fig">Fig. 2B</xref>).</p>
    </sec>
    <sec>
      <title>3.2 Analysis of splice variant neoantigens in TCGA LAML</title>
      <p>To elucidate the splice variant neoantigen landscape of various cancer types, we next performed NeoSplice analysis in the TCGA LAML dataset. To assess the distribution of splice variant neoantigens in different types of cancer, NeoSplice was run on TCGA LAML samples (<italic toggle="yes">n</italic> = 137) using healthy donor bone marrow-derived CD34+ hematopoietic stem cells as a reference normal. Of 19 970 total genes that showed expression, 316 demonstrated splice variants, representing 1872 unique predicted MHC binding peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A and B</xref>). Among predicted splice variants, the derivative genes were often shared between samples, including 34 genes contained within the predicted splice variants of &gt;5% of samples (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C</xref>). The most prominent of these genes was MPO, seen in ∼35% (48 of 137) of samples. The number of SNV and splice variant neoantigens were similar with TCGA LAML (<xref rid="vbac032-F3" ref-type="fig">Fig. 3A</xref>; median count per sample: SNV = 14, splice variant = 17; Welch <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> = 0.18). We did not observe a significant difference in splice variant neoantigen levels between samples containing spliceosomal mutations in <italic toggle="yes">U2AF1</italic>, <italic toggle="yes">SRSF2</italic> or <italic toggle="yes">SF3B1</italic> genes (median = 15; SD 13.0) versus those without these spliceosomal mutations (median = 17; SD 22.9). While SNV neoantigens are generally patient-specific, we observed sharing of splice variant neoantigens across TCGA samples, including seven splice variant neoantigens that were observed in &gt;10% (&gt;13) of all TCGA LAML samples (<xref rid="vbac032-F3" ref-type="fig">Fig. 3B</xref>).</p>
      <fig position="float" id="vbac032-F3">
        <label>Fig. 3.</label>
        <caption>
          <p>Comparison of single-nucleotide variant (SNV) and splice variant (SV) antigen calls in the TCGA LAML dataset. (<bold>A</bold>) Number of HLA-I SNV and SV antigen calls per TCGA LAML sample, defined as netMHCpan4.0 predicted binding affinity &lt;500 nM. (<bold>B</bold>) Histogram showing proportion of public SNV or SV antigens shared among TCGA LAML samples</p>
        </caption>
        <graphic xlink:href="vbac032f3" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.3 Mass spectrometry validation of NeoSplice predicted antigens</title>
      <p>To biologically validate NeoSplice predicted splice variant neoantigens, a set of <bold>N</bold> neoantigen peptides predicted in the K562.A2 cell line (an AML cell line engineered to express HLA-A*02:01) were synthesized. HLA-A*02:01 binding peptides were isolated from K562.A2 cells using anti-HLA-A*02-based immunoprecipitation and column purification/acid elution of the MHC-bound peptides. Using synthesized peptides as reference for electrospray ionization coupled to differential ion mobility spectrometry-mass spectrometry (ESI-DIMS-MS), we searched for the presence of these predicted splice variant neoantigens in the K562.A2 MHC ligand pool. Comparing MS/MS spectra from K562.A2 to a spectral library of predicted peptide standards obtained using the same instrumental conditions, we identified 4/37 (10.8%) of predicted antigens from the immunopeptidome of one K562.A2 sample, which corresponded to 3/17 (17.4%) unique predicted splice junctions identified by MS (<xref rid="vbac032-F4" ref-type="fig">Fig. 4</xref>).</p>
      <fig position="float" id="vbac032-F4">
        <label>Fig. 4.</label>
        <caption>
          <p>Mass spectrometric analysis of the K562.A2 cell line HLA-I immunopeptidome versus NeoSplice predicted peptides. MS spectra from K562.A2 anti-HLA-A*02-based immunoprecipitation and column purification/acid elution of MHC-bound peptides (left) alongside the matching peptide standard from NeoSplice predicted antigens from the K562-A2 cell line (right). Fit (F) score for each peptide is shown (right).</p>
        </caption>
        <graphic xlink:href="vbac032f4" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>3.4 Comparison of NeoSplice with other methods for splice variant neoantigen prediction</title>
      <p><xref rid="vbac032-T1" ref-type="table">Table 1</xref> compares NeoSplice with eight other methods for prediction of splice variants. While the majority of these tools only predict novel splice junctions, NeoSplice, ASNEO and the RI neoantigen pipeline further predict the neoantigens derived from these splice junctions. MutPred Splice and MiSplice are unique in using DNA-seq data to predict for somatic variants that may disrupt normal splicing of mRNA, while remaining tools are similar to NeoSplice in predicting splice variants using RNA-seq data only.</p>
      <table-wrap position="float" id="vbac032-T1">
        <label>Table 1.</label>
        <caption>
          <p>Comparison of splice variant prediction tools from the literature with NeoSplice</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
            <col valign="top" align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Splice variant antigen caller</th>
              <th rowspan="1" colspan="1">Input</th>
              <th rowspan="1" colspan="1">Predicts neoantigens</th>
              <th rowspan="1" colspan="1">Splicing event identified</th>
              <th rowspan="1" colspan="1">Required packages</th>
              <th rowspan="1" colspan="1"><italic toggle="yes">In silico</italic> performance</th>
              <th rowspan="1" colspan="1">Wet lab validation</th>
              <th rowspan="1" colspan="1">Wet lab performance</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">ASNEO</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">Yes</td>
              <td rowspan="1" colspan="1">Filters reads against GTEx and hg19 reference, translating novel isoforms into proteins for antigen prediction.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Python: sj2psi</p>
                  </list-item>
                  <list-item>
                    <p>R: survival, survminer, MCPcounter</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Not reported</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">Mass spectrometry (external dataset)</td>
              <td rowspan="1" colspan="1">2/407 peptides confirmed from 14 patient cohort</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">JuncBase</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">(1) Identifies annotated and novel splice junctions, (2) quantifies each junction and (3) calculated for differential expression between groups.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Python 2.6+</p>
                  </list-item>
                  <list-item>
                    <p>Biopython 1.5+</p>
                  </list-item>
                  <list-item>
                    <p>Pysam</p>
                  </list-item>
                  <list-item>
                    <p>R v2.14+</p>
                  </list-item>
                  <list-item>
                    <p>Rpy2</p>
                  </list-item>
                  <list-item>
                    <p>MySQL/sqlite</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. ∼50–80%</p>
                  </list-item>
                  <list-item>
                    <p>Prec. ∼10–95%</p>
                  </list-item>
                  <list-item>
                    <p>(Compared in Kahles <italic toggle="yes">et al.</italic>)</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">RT-PCR</td>
              <td rowspan="1" colspan="1">16/16 splicing events confirmed</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MiSplice</td>
              <td rowspan="1" colspan="1">RNA-seq + WGS</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Jointly analyzes WGS and RNA-Seq data, scanning the transcriptome for statistically significant non-canonical sequence junctions supported by expression evidence.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>SamTools</p>
                  </list-item>
                  <list-item>
                    <p>MaxEntScan</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. 74–97%</p>
                  </list-item>
                  <list-item>
                    <p>Spec. ∼77%</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">Splicing reporter minigene functional assay</td>
              <td rowspan="1" colspan="1">10/11 of splicing alterations</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MutPred Splice</td>
              <td rowspan="1" colspan="1">DNAseq</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Uses human disease alleles for training a machine learning model to predict exonic nucleotide substitutions that disrupt pre-mRNA splicing.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>None (web interface)</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>FPR = 7.0%</p>
                  </list-item>
                  <list-item>
                    <p>Sens. 64.7%</p>
                  </list-item>
                  <list-item>
                    <p>Spec. 93.0%</p>
                  </list-item>
                  <list-item>
                    <p>Acc. 78.8%</p>
                  </list-item>
                  <list-item>
                    <p>AUC 83.5%</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">RT-PCR</td>
              <td rowspan="1" colspan="1">Amplicon changes from ATM mutation-contain vs WT cell line confirmed by RT-PCR</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">NeoSplice</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">Yes</td>
              <td rowspan="1" colspan="1">(1) Identify differentially expressed k-mers, (2) map tumor-specific k-mers to splice graph and (3) ORF inference, translation, and MHC binding prediction.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Python 2.7</p>
                  </list-item>
                  <list-item>
                    <p>MSBWT</p>
                  </list-item>
                  <list-item>
                    <p>MSBWT-IS</p>
                  </list-item>
                  <list-item>
                    <p>NetMHCpan 4.0</p>
                  </list-item>
                  <list-item>
                    <p>NetMHCIIpan 3.2</p>
                  </list-item>
                  <list-item>
                    <p>networkx 1.11</p>
                  </list-item>
                  <list-item>
                    <p>pyahocorasick 1.4.0</p>
                  </list-item>
                  <list-item>
                    <p>bcbio-gff 0.6.4</p>
                  </list-item>
                  <list-item>
                    <p>pyfaidx 0.5.3.1</p>
                  </list-item>
                  <list-item>
                    <p>pysam 0.14.1</p>
                  </list-item>
                  <list-item>
                    <p>biopython 1.70</p>
                  </list-item>
                  <list-item>
                    <p>scipy 1.2.0</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. &gt;80%</p>
                  </list-item>
                  <list-item>
                    <p>Recall &gt;80%</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">Internal mass spectrometry validation against synthetic peptide reference</td>
              <td rowspan="1" colspan="1">4/37 peptides confirmed, corresponding to 3/17 novel splice junctions</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">RI neoantigen pipeline</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">Yes</td>
              <td rowspan="1" colspan="1">(1) Pseudoaligns RNAseq reads to hg19 with exon and intron transcripts, (2) quantification, (3) KMA algorithm to identify expresed introns and (4) predict MHC binding.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Kallisto</p>
                  </list-item>
                  <list-item>
                    <p>KMA suite of python and R packages</p>
                  </list-item>
                  <list-item>
                    <p>POLYSOLVER</p>
                  </list-item>
                  <list-item>
                    <p>NetMHCpan v3.1</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Not reported</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">Mass spectrometry (external dataset)</td>
              <td rowspan="1" colspan="1">Confirmed 1–2 per each of six cell line tested (Mean total splice variant neantigen load of 1515)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">rMATS</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">Detection of differentially expressed splice variants between two sets of RNA-seq data.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Python 2.7/3.6</p>
                  </list-item>
                  <list-item>
                    <p>BLAS, LAPACK</p>
                  </list-item>
                  <list-item>
                    <p>GSL 2.5</p>
                  </list-item>
                  <list-item>
                    <p>GCC (5.4.0)</p>
                  </list-item>
                  <list-item>
                    <p>Fortran 77</p>
                  </list-item>
                  <list-item>
                    <p>CMake (3.15.4)</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. ∼30%</p>
                  </list-item>
                  <list-item>
                    <p>Prec. &gt;95%</p>
                  </list-item>
                  <list-item>
                    <p>(Compared in Kahles <italic toggle="yes">et al.</italic> for exon skipping only)</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">RT-PCR</td>
              <td rowspan="1" colspan="1">32/34 exon skipping candidates confirmed</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SplAdder</td>
              <td rowspan="1" colspan="1">RNA-seq</td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">(1) Integrating annotation and RNA-Seq data, (2) generating an augmented splicing graph, (3) extraction of splicing events, (4) quantifying the events, and optionally and (5) the differential analysis between samples.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>LIMIX</p>
                  </list-item>
                  <list-item>
                    <p>GATK</p>
                  </list-item>
                  <list-item>
                    <p>STAR</p>
                  </list-item>
                  <list-item>
                    <p>Samtools</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. ∼30–80%</p>
                  </list-item>
                  <list-item>
                    <p>Prec. ∼20–90%</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SpliceGrapher</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>RNA-seq</p>
                  </list-item>
                  <list-item>
                    <p>+/-EST</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">No</td>
              <td rowspan="1" colspan="1">(1) Alignment of RNA-seq to the reference genome, (2) spliced alignment of reads that did not align in the first step, (3) initial splice graph construction, (4) assembly of exons from the ungapped short-read alignments and (5) insertion of the new exons into the splice graph using spliced alignments.</td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>PyML 0.7.9+</p>
                  </list-item>
                  <list-item>
                    <p>matplotlib 1.1.0+</p>
                  </list-item>
                  <list-item>
                    <p>pysam 0.5+</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">
                <list list-type="simple">
                  <list-item>
                    <p>Sens. ∼30–60%</p>
                  </list-item>
                  <list-item>
                    <p>Prec. ∼20–90%</p>
                  </list-item>
                  <list-item>
                    <p>(Compared in Kahles <italic toggle="yes">et al.</italic>)</p>
                  </list-item>
                </list>
              </td>
              <td rowspan="1" colspan="1">None</td>
              <td rowspan="1" colspan="1">NA</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>An important difference between these splice variant calling tools are the methods utilized to validate the predictions. Several tools (SplAdder, SpliceGrapher) did not report any wet lab validation studies, while the majority reported RT-PCR based strategies to confirm splice products. Only three tools included mass spectrometry validation of the translated protein products from predicted splice variant neoantigens: ASNEO, the RI neoantigen pipeline, and NeoSplice. <xref rid="vbac032-B34" ref-type="bibr">Smart <italic toggle="yes">et al.</italic> (2018)</xref> (RI neoantigen pipeline) utilized mass spectrometry to validate predicted neoepitopes and identified 1–2 of the 5000–10 000 predicted RI neoepitopes and 0–2 of the 400–10 000 predicted somatic neoepitopes per cell line tested. <xref rid="vbac032-B41" ref-type="bibr">Zhang <italic toggle="yes">et al.</italic> (2020)</xref> (ASNEO) confirmed 2 of 407 predicted MHC-I neoantigens by mass spectrometry. In comparison, our study identified 4 of 37 peptides by mass spectrometry, including validation of 3 of 17 unique splice junctions. In contrast to the two above studies, the mass spectrometry method described in this study used a synthetic peptide reference to compare the immunopeptidome spectra against, increasing the confidence of validated peptides. Although the percentage of confirmed antigens cannot be directly compared between our method versus the two above studies, the increased sensitivity and accuracy of having a peptide reference allowed for validation of a much higher percentage of tested splice variant neoantigens.</p>
    </sec>
  </sec>
  <sec>
    <title>4 Discussion</title>
    <p>In this report, we describe NeoSplice, a bioinformatics tool for prediction of splice variant neoantigens from RNA-seq data. The performance comparison results from the simulated data indicates that predictions made by NeoSplice are highly sensitive and precise. Moreover, NeoSplice is a time and space efficient algorithm. Our novel BWT-based tumor-specific k-mer searching algorithm does not need to examine all possible k-mers in tumor and normal RNA-seq data, and the BWT method requires less memory compared to hash-table based methods that usually require large memory to build an index. The splice graph building step requires time proportional to the number of reads in the data set and the splice variant peptide prediction step requires time proportional to the number of edges and nodes in the connected component that contains the tumor-specific splice junction. Moreover, NeoSplice can be extended to predict neoantigens derived from other types of mutations such as SNVs, indels, and gene fusions as identification of tumor-specific k-mers should capture each of these and the splice graph traversal will identify the transcripts that contain tumor-specific mutations.</p>
    <p>In contrast to SNV-derived neoantigens, many splice variant neoantigens are found to be shared among different AML tumors in our analysis, suggesting the feasibility to develop an off-the-shelf splice variant neoantigen therapeutic. We expect that NeoSplice will expand the neoantigen therapeutic target space for cancer patients, possibly providing an avenue for off-the-shelf therapeutics. Currently, there are over 160 clinical trials of therapeutic neoantigen vaccines in cancer registered on ClinicalTrials.gov. Multiple companies have others, along with neoantigen-specific adoptive cellular therapy approaches, in development. Accurate identification of splice variant neoantigens will become more important as additional neoantigen-specific therapeutic platforms enter clinical trials, especially for those tumors like AML where neoantigens derived from SNVs and Indels are rare.</p>
    <p>NeoSplice provides several improvements upon current splice variant prediction methods described in the literature. Firstly, NeoSplice is one of few tools that incorporates alternative splice prediction alongside antigen prediction. This is bolstered by the capacity of NeoSplice to predict the full length splice variant transcript upstream of novel splice junction and the partial splice variant transcript downstream of novel splice junction, with open reading frame inference to predict for the in-frame peptide. Secondly, NeoSplice performed very well with <italic toggle="yes">in silico</italic> validation, with sensitivity and precision &gt;80% for the majority of simulated splice variant transcripts, which is significantly higher compared against a recently published splice variant prediction tool ASNEO. Importantly, NeoSplice’s superior performance may be attributable to both the algorithm itself as well as the use of the newer hg38 reference, which matched the reference used to generate the simulated dataset. This comparison ideally should be performed using an updated version of ASNEO containing the hg38 reference; however, ASNEO’s resources did not contain information on how to exchange the built-in reference. Notably, hg38 contains more comprehensive annotations for splice junctions and should ideally be used for best splice variant prediction performance. This also highlights NeoSplice’s advantage in being able to adapt newer references as they are developed. In addition to ASNEO, most other tools did not provide <italic toggle="yes">in silico</italic> validation performance, making it difficult to interpret the robustness of the tool for downstream antigen selection. Thirdly, we also report here the runtime and memory requirements for NeoSplice—an important consideration given the computationally intensive nature of predicting for alternative splice variants and limited timeframe for selection of cancer antigen targets for therapeutic vaccine development. Similarly, these characteristics are not widely reported in other tools. NeoSplice’s efficiency allows for large datasets (such as TCGA cohorts) to be analyzed, with runtimes that are compatible with timelines for cancer antigen vaccine development. Lastly, our mass spectrometry validation approach is a unique strength of this study. Unlike previous studies that also examined mass spectrometry data, this is the first study to our knowledge that generated internal mass spectrometry data and used synthetic reference peptides to compare against immunopeptidome spectra. As such, while a smaller percentage of total predicted splice variant antigens were tested, the confidence of the positive mass spectrometry hits was increased. Additionally, while we tested only 37 peptides, we were able to validate &gt;10% of antigens comprising &gt;17% of all unique splice variant transcripts contained in the reference set of peptides. Given the sensitivity of mass spectrometry is imperfect, we expect the true positive rate to be further increased from these estimates. Lastly, we only used mass spectrometry evaluation of a subset of peptides selected as optimal vaccine candidates. As such, our validation provides a more direct metric for likelihood of a valid vaccine candidate, as compared to previous studies which evaluated the entire pool of predicted splice variant neoantigens. We believe the validation provided in this study is the most biologically robust of any currently described method, with greatest relevance for downstream antigen-specific therapeutics. Overall, we believe these advantages make NeoSplice a powerful tool for predicting splice variant neoantigens, providing the computational framework for future studies to test the efficacy of splice variant targeted vaccine and cellular therapies.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work has been supported by the National Institutes of Health Clinical Center (1F30CA225136, 5R01CA201225, R37CA247676 and T32CA196589) and the University of North Carolina University Cancer Research Fund.</p>
    <p><italic toggle="yes">Conflict of Interest:</italic> B.G.V. has equity in GeneCentric Therapeutics.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data Availability Statement</title>
    <p>The data underlying this article are available in the article and in its online supplementary material.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>vbac032_Supplementary_Data</label>
      <media xlink:href="vbac032_supplementary_data.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="vbac032-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brooks</surname><given-names>A.N.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events</article-title>. <source>PLoS One</source>, <volume>9</volume>, <fpage>e87361</fpage>.<pub-id pub-id-type="pmid">24498085</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B2">
      <mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Research Network</collab><etal>et al</etal> (<year>2013</year>) <article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title>. <source>New Engl. J. Med</source>., <volume>368</volume>, <fpage>2059</fpage>–<lpage>2074</lpage>.<pub-id pub-id-type="pmid">23634996</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Church</surname><given-names>D.M.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>Modernizing reference genome assemblies</article-title>. <source>PLoS Biol</source>., <volume>9</volume>, <fpage>e1001091</fpage>.<pub-id pub-id-type="pmid">21750661</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Necochea-Campion</surname><given-names>R.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Aberrant splicing and drug resistance in AML</article-title>. <source>J. Hematol. Oncol</source>., <volume>9, 85</volume>.</mixed-citation>
    </ref>
    <ref id="vbac032-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>, <volume>29</volume>, <fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ehx</surname><given-names>G.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes</article-title>. <source>Immunity</source>, <volume>54</volume>, <fpage>737</fpage>–<lpage>752.e10</lpage>.<pub-id pub-id-type="pmid">33740418</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frazee</surname><given-names>A.C.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>Polyester: simulating RNA-seq datasets with differential transcript expression</article-title>. <source>Bioinformatics</source>, <volume>31</volume>, <fpage>2778</fpage>–<lpage>2784</lpage>.<pub-id pub-id-type="pmid">25926345</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B8">
      <mixed-citation publication-type="journal"><collab>GTEx Consortium</collab><etal>et al</etal> (<year>2017</year>) <article-title>Genetic effects on gene expression across human tissues</article-title>. <source>Nature</source>, <volume>550</volume>, <fpage>204</fpage>–<lpage>213</lpage>.<pub-id pub-id-type="pmid">29022597</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hellmann</surname><given-names>M.D.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden</article-title>. <source>New Engl. J. Med</source>., <volume>378</volume>, <fpage>2093</fpage>–<lpage>2104</lpage>.<pub-id pub-id-type="pmid">29658845</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hodi</surname><given-names>F.S.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) <article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title>. <source>New Engl. J. Med</source>., <volume>363</volume>, <fpage>711</fpage>–<lpage>723</lpage>.<pub-id pub-id-type="pmid">20525992</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hundal</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>pVAC-Seq: a genome-guided <italic toggle="yes">in silico</italic> approach to identifying tumor neoantigens</article-title>. <source>Genome Med</source>., <volume>8</volume>, <fpage>11</fpage>.<pub-id pub-id-type="pmid">26825632</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ito</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2015</year>) <article-title>Cancer neoantigens: a promising source of immunogens for cancer immunotherapy</article-title>. <source>J. Clin. Cell Immunol</source>., <volume>6, 2</volume>.</mixed-citation>
    </ref>
    <ref id="vbac032-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jayasinghe</surname><given-names>R.G.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Systematic analysis of splice-site-creating mutations in cancer</article-title>. <source>Cell Rep</source>., <volume>23</volume>, <fpage>270</fpage>–<lpage>281.e3</lpage>.<pub-id pub-id-type="pmid">29617666</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jurtz</surname><given-names>V.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data</article-title>. <source>J. Immunol</source>., <volume>199</volume>, <fpage>3360</fpage>–<lpage>3368</lpage>.<pub-id pub-id-type="pmid">28978689</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahles</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data</article-title>. <source>Bioinformatics</source>, <volume>32</volume>, <fpage>1840</fpage>–<lpage>1847</lpage>.<pub-id pub-id-type="pmid">26873928</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahles</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Comprehensive analysis of alternative splicing across tumors from 8,705 patients</article-title>. <source>Cancer Cell</source>, <volume>34</volume>, <fpage>211</fpage>–<lpage>224.e6</lpage>.<pub-id pub-id-type="pmid">30078747</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kardos</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</article-title>. <source>JCI Insight</source>, <volume>1</volume>, <fpage>e85902</fpage>.<pub-id pub-id-type="pmid">27699256</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keren</surname><given-names>H.</given-names></string-name></person-group><etal>et al</etal> (<year>2010</year>) <article-title>Alternative splicing and evolution: diversification, exon definition and function</article-title>. <source>Nat. Rev. Genet</source>., <volume>11</volume>, <fpage>345</fpage>–<lpage>355</lpage>.<pub-id pub-id-type="pmid">20376054</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keskin</surname><given-names>D.B.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial</article-title>. <source>Nature</source>, <volume>565</volume>, <fpage>234</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">30568305</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information</article-title>. <source>Ann. Oncol</source>., <volume>29</volume>, <fpage>1030</fpage>–<lpage>1036</lpage>.<pub-id pub-id-type="pmid">29360924</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larkin</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Five-year survival with combined nivolumab and ipilimumab in advanced melanoma</article-title>. <source>New Engl. J. Med</source>., <volume>381</volume>, <fpage>1535</fpage>–<lpage>1546</lpage>.<pub-id pub-id-type="pmid">31562797</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>S.C.-W.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins</article-title>. <source>Nat. Med</source>., <volume>22</volume>, <fpage>672</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">27135740</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lozzio</surname><given-names>C.B.</given-names></string-name>, <string-name><surname>Lozzio</surname><given-names>B.B.</given-names></string-name></person-group> (<year>1975</year>) <article-title>Human chronic myelogenous leukemia cell-line with positive philadelphia chromosome</article-title>. <source>Blood</source>, <volume>45</volume>, <fpage>321</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">163658</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mort</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>MutPred splice: machine learning-based prediction of exonic variants that disrupt splicing</article-title>. <source>Genome Biol</source>., <volume>15</volume>, <fpage>R19</fpage>.<pub-id pub-id-type="pmid">24451234</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mose</surname><given-names>L.E.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Improved indel detection in DNA and RNA via realignment with ABRA2</article-title>. <source>Bioinformatics</source>, <volume>35</volume>, <fpage>2966</fpage>–<lpage>2973</lpage>.<pub-id pub-id-type="pmid">30649250</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ott</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title>. <source>Nature</source>, <volume>547</volume>, <fpage>217</fpage>–<lpage>221</lpage>.<pub-id pub-id-type="pmid">28678778</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>SLC45A2: a melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity</article-title>. <source>Cancer Immunol. Res</source>., <volume>5</volume>, <fpage>618</fpage>–<lpage>629</lpage>.<pub-id pub-id-type="pmid">28630054</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rajasagi</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia</article-title>. <source>Blood</source>, <volume>124</volume>, <fpage>453</fpage>–<lpage>462</lpage>.<pub-id pub-id-type="pmid">24891321</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>M.F.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) <article-title>SpliceGrapher: detecting patterns of alternative splicing from RNA-Seq data in the context of gene models and EST data</article-title>. <source>Genome Biol</source>., <volume>13</volume>, <fpage>R4</fpage>.<pub-id pub-id-type="pmid">22293517</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sahin</surname><given-names>U.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title>. <source>Nature</source>, <volume>547</volume>, <fpage>222</fpage>–<lpage>226</lpage>.<pub-id pub-id-type="pmid">28678784</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schreiber</surname><given-names>R.D.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion</article-title>. <source>Science</source>, <volume>331</volume>, <fpage>1565</fpage>–<lpage>1570</lpage>.<pub-id pub-id-type="pmid">21436444</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schumacher</surname><given-names>T.N.</given-names></string-name>, <string-name><surname>Schreiber</surname><given-names>R.D.</given-names></string-name></person-group> (<year>2015</year>) <article-title>Neoantigens in cancer immunotherapy</article-title>. <source>Science</source>, <volume>348</volume>, <fpage>69</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">25838375</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>111</volume>, <fpage>E5593</fpage>–<lpage>E601</lpage>.<pub-id pub-id-type="pmid">25480548</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smart</surname><given-names>A.C.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Intron retention is a source of neoepitopes in cancer</article-title>. <source>Nat. Biotechnol</source>., <volume>36</volume>, <fpage>1056</fpage>–<lpage>1058</lpage>.<pub-id pub-id-type="pmid">30114007</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>C.C.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Alternative tumour-specific antigens</article-title>. <source>Nat. Rev. Cancer</source>, <volume>19</volume>, <fpage>465</fpage>–<lpage>478</lpage>.<pub-id pub-id-type="pmid">31278396</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>C.C.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes</article-title>. <source>Cancer Immunol. Res</source>., <volume>7</volume>, <fpage>1591</fpage>–<lpage>1604</lpage>.<pub-id pub-id-type="pmid">31515258</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szolek</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>OptiType: precision HLA typing from next-generation sequencing data</article-title>. <source>Bioinformatics</source>, <volume>30</volume>, <fpage>3310</fpage>–<lpage>3316</lpage>.<pub-id pub-id-type="pmid">25143287</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorsson</surname><given-names>V.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>The immune landscape of cancer</article-title>. <source>Immunity</source>, <volume>51</volume>, <fpage>411</fpage>–<lpage>412</lpage>.<pub-id pub-id-type="pmid">31433971</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turajlic</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis</article-title>. <source>Lancet Oncol</source>., <volume>18</volume>, <fpage>1009</fpage>–<lpage>1021</lpage>.<pub-id pub-id-type="pmid">28694034</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yarchoan</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Targeting neoantigens to augment antitumour immunity</article-title>. <source>Nat. Rev. Cancer</source>, <volume>17</volume>, <fpage>209</fpage>–<lpage>222</lpage>.<pub-id pub-id-type="pmid">28233802</pub-id></mixed-citation>
    </ref>
    <ref id="vbac032-B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Z.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>ASNEO: identification of personalized alternative splicing based neoantigens with RNA-seq</article-title>. <source>Aging</source>, <volume>12</volume>, <fpage>14633</fpage>–<lpage>14648</lpage>.<pub-id pub-id-type="pmid">32697765</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
